Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
|Articles|September 8, 2021
Pharmacy Clinical Pearl of the Day: Ulcerative Colitis
Author(s)Saro Arakelians, PharmD
Ulcerative colitis affects the innermost lining of your large intestine and rectum.
Advertisement
Clinical Pearl of the Day: Ulcerative Colitis
Ulcerative colitis is an inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the digestive tract.
Explanation:
- Ulcerative colitis affects the innermost lining of your large intestine (colon) and rectum.
- Symptoms usually develop over time, rather than suddenly, and include diarrhea, abdominal pain, cramping, rectal pain, rectal bleeding, urgency to defecate, weight loss, fatigue, fever, and failure to grow in children.
- Risk factors may include age, race or ethnicity, and family history.
- Treatment may include anti-inflammatory drugs such as 5-aminosalicylates and corticosteroids; immune system suppressants such as azathioprine, cyclosporine, and Xeljanz; biologics such as Remicade, Entyvio, and Stelara; and anti-diarrheal medications, pain relievers, antispasmodics, and iron supplements.
Reference:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5